These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 16409557

  • 1. SUMOylation substrates in neuronal intranuclear inclusion disease.
    Takahashi-Fujigasaki J, Arai K, Funata N, Fujigasaki H.
    Neuropathol Appl Neurobiol; 2006 Feb; 32(1):92-100. PubMed ID: 16409557
    [Abstract] [Full Text] [Related]

  • 2. Neuronal intranuclear inclusion disease without polyglutamine inclusions in a child.
    McFadden K, Hamilton RL, Insalaco SJ, Lavine L, Al-Mateen M, Wang G, Wiley CA.
    J Neuropathol Exp Neurol; 2005 Jun; 64(6):545-52. PubMed ID: 15977647
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease.
    Pountney DL, Huang Y, Burns RJ, Haan E, Thompson PD, Blumbergs PC, Gai WP.
    Exp Neurol; 2003 Nov; 184(1):436-46. PubMed ID: 14637113
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
    Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, Palvimo JJ, Hay RT.
    Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
    Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, Zhou J, Zhu J, Raught B, de Thé H.
    Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733
    [Abstract] [Full Text] [Related]

  • 14. NSF, Unc-18-1, dynamin-1 and HSP90 are inclusion body components in neuronal intranuclear inclusion disease identified by anti-SUMO-1-immunocapture.
    Pountney DL, Raftery MJ, Chegini F, Blumbergs PC, Gai WP.
    Acta Neuropathol; 2008 Dec; 116(6):603-14. PubMed ID: 18836734
    [Abstract] [Full Text] [Related]

  • 15. The PML-nuclear inclusion of human supraoptic neurons: a new compartment with SUMO-1- and ubiquitin-proteasome-associated domains.
    Villagra NT, Navascues J, Casafont I, Val-Bernal JF, Lafarga M, Berciano MT.
    Neurobiol Dis; 2006 Jan; 21(1):181-93. PubMed ID: 16125395
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling.
    Bailey D, O'Hare P.
    Biochem J; 2005 Dec 01; 392(Pt 2):271-81. PubMed ID: 16117725
    [Abstract] [Full Text] [Related]

  • 17. Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies.
    Janssen K, Hofmann TG, Jans DA, Hay RT, Schulze-Osthoff K, Fischer U.
    Oncogene; 2007 Mar 08; 26(11):1557-66. PubMed ID: 16924230
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.